Expression	0	10	O
and	11	14	O
purification	15	27	O
of	28	30	O
the	31	34	O
catalytic	35	44	O
domain	45	51	O
of	52	54	O
human	55	60	B-Organism
vascular	61	69	B-Gene_or_gene_product
endothelial	70	81	I-Gene_or_gene_product
growth	82	88	I-Gene_or_gene_product
factor	89	95	I-Gene_or_gene_product
receptor	96	104	I-Gene_or_gene_product
2	105	106	I-Gene_or_gene_product
for	107	110	O
inhibitor	111	120	O
screening	121	130	O
.	130	131	O

Vascular	133	141	B-Gene_or_gene_product
endothelial	142	153	I-Gene_or_gene_product
growth	154	160	I-Gene_or_gene_product
factor	161	167	I-Gene_or_gene_product
(	168	169	O
VEGF	169	173	B-Gene_or_gene_product
)	173	174	O
,	174	175	O
an	176	178	O
endothelial	179	190	B-Cell
cell	191	195	I-Cell
-	195	196	O
specific	196	204	O
mitogen	205	212	O
,	212	213	O
can	214	217	O
act	218	221	O
in	222	224	O
tumor	225	230	B-Pathological_formation
-	230	231	O
induced	231	238	O
angiogenesis	239	251	O
by	252	254	O
binding	255	262	O
to	263	265	O
specific	266	274	O
receptors	275	284	O
on	285	287	O
the	288	291	O
surface	292	299	O
of	300	302	O
endothelial	303	314	B-Cell
cells	315	320	I-Cell
.	320	321	O

One	322	325	O
such	326	330	O
receptor	331	339	O
,	339	340	O
VEGFR	341	346	B-Gene_or_gene_product
-	346	347	I-Gene_or_gene_product
2	347	348	I-Gene_or_gene_product
/	348	349	O
KDR	349	352	B-Gene_or_gene_product
,	352	353	O
plays	354	359	O
a	360	361	O
key	362	365	O
role	366	370	O
in	371	373	O
VEGF	374	378	B-Gene_or_gene_product
-	378	379	O
induced	379	386	O
angiogenesis	387	399	O
.	399	400	O

Here	401	405	O
,	405	406	O
we	407	409	O
expressed	410	419	O
the	420	423	O
catalytic	424	433	O
domain	434	440	O
of	441	443	O
VEGFR	444	449	B-Gene_or_gene_product
-	449	450	I-Gene_or_gene_product
2	450	451	I-Gene_or_gene_product
as	452	454	O
a	455	456	O
soluble	457	464	O
active	465	471	O
kinase	472	478	O
using	479	484	O
Bac	485	488	O
-	488	489	O
to	489	491	O
-	491	492	O
Bac	492	495	O
expression	496	506	O
system	507	513	O
,	513	514	O
and	515	518	O
investigated	519	531	O
correlations	532	544	O
between	545	552	O
VEGFR	553	558	B-Gene_or_gene_product
-	558	559	I-Gene_or_gene_product
2	559	560	I-Gene_or_gene_product
activity	561	569	O
and	570	573	O
enzyme	574	580	O
concentration	581	594	O
,	594	595	O
ATP	596	599	B-Drug_or_compound
concentration	600	613	O
,	613	614	O
substrate	615	624	O
concentration	625	638	O
and	639	642	O
divalent	643	651	O
cation	652	658	O
type	659	663	O
.	663	664	O

We	665	667	O
used	668	672	O
these	673	678	O
data	679	683	O
to	684	686	O
establish	687	696	O
a	697	698	O
convenient	699	709	O
,	709	710	O
effective	711	720	O
and	721	724	O
non	725	728	O
-	728	729	O
radioactive	729	740	O
ELISA	741	746	O
screening	747	756	O
technique	757	766	O
for	767	770	O
the	771	774	O
identification	775	789	O
and	790	793	O
evaluation	794	804	O
of	805	807	O
potential	808	817	O
inhibitors	818	828	O
for	829	832	O
VEGFR	833	838	B-Gene_or_gene_product
-	838	839	I-Gene_or_gene_product
2	839	840	I-Gene_or_gene_product
kinase	841	847	O
.	847	848	O

We	849	851	O
screened	852	860	O
200	861	864	O
RTK	865	868	O
target	869	875	O
-	875	876	O
based	876	881	O
compounds	882	891	O
and	892	895	O
identified	896	906	O
one	907	910	O
(	911	912	O
TKI	912	915	B-Drug_or_compound
-	915	916	I-Drug_or_compound
31	916	918	I-Drug_or_compound
)	918	919	O
that	920	924	O
potently	925	933	O
inhibited	934	943	O
VEGFR	944	949	B-Gene_or_gene_product
-	949	950	I-Gene_or_gene_product
2	950	951	I-Gene_or_gene_product
kinase	952	958	O
activity	959	967	O
(	968	969	O
IC50	969	973	O
=	973	974	O
0	974	975	O
.	975	976	O
596	976	979	O
microM	980	986	O
)	986	987	O
.	987	988	O

Treatment	989	998	O
of	999	1001	O
NIH3T3	1002	1008	B-Cell
/	1008	1009	I-Cell
KDR	1009	1012	I-Cell
cells	1013	1018	I-Cell
with	1019	1023	O
TKI	1024	1027	B-Drug_or_compound
-	1027	1028	I-Drug_or_compound
31	1028	1030	I-Drug_or_compound
blocked	1031	1038	O
VEGF	1039	1043	B-Gene_or_gene_product
-	1043	1044	O
induced	1044	1051	O
phosphorylation	1052	1067	O
of	1068	1070	O
KDR	1071	1074	B-Gene_or_gene_product
in	1075	1077	O
a	1078	1079	O
dose	1080	1084	O
-	1084	1085	O
dependent	1085	1094	O
manner	1095	1101	O
.	1101	1102	O

Moreover	1103	1111	O
,	1111	1112	O
TKI	1113	1116	B-Drug_or_compound
-	1116	1117	I-Drug_or_compound
31	1117	1119	I-Drug_or_compound
dose	1120	1124	O
-	1124	1125	O
dependently	1125	1136	O
suppressed	1137	1147	O
HUVEC	1148	1153	B-Tissue
tube	1154	1158	I-Tissue
formation	1159	1168	O
.	1168	1169	O

Thus	1170	1174	O
,	1174	1175	O
we	1176	1178	O
herein	1179	1185	O
report	1186	1192	O
a	1193	1194	O
novel	1195	1200	O
,	1200	1201	O
efficient	1202	1211	O
method	1212	1218	O
for	1219	1222	O
identifying	1223	1234	O
VEGFR	1235	1240	B-Gene_or_gene_product
-	1240	1241	I-Gene_or_gene_product
2	1241	1242	I-Gene_or_gene_product
kinase	1243	1249	O
inhibitors	1250	1260	O
and	1261	1264	O
introduce	1265	1274	O
one	1275	1278	O
,	1278	1279	O
TKI	1280	1283	B-Drug_or_compound
-	1283	1284	I-Drug_or_compound
31	1284	1286	I-Drug_or_compound
,	1286	1287	O
that	1288	1292	O
may	1293	1296	O
prove	1297	1302	O
to	1303	1305	O
be	1306	1308	O
a	1309	1310	O
useful	1311	1317	O
new	1318	1321	O
angiogenesis	1322	1334	O
inhibitor	1335	1344	O
.	1344	1345	O

